Truveta Rolls Out Early Health Data Platform, Adds Partners

Seattle-based startup Truveta has rolled out an early version of its real-time health data platform, the company announced Tuesday (Nov. 9).

Alongside the Truveta Platform, the company is expanding its clinical care reach by partnering with three new healthcare providers — Louisiana-based Ochsner Health, Kansas’s Saint Luke’s Health System, and Iowa-based UnityPoint Health.

“Together, we can learn from each other, collaborate on new insights, and ultimately better serve patients in our communities while advancing our united vision of saving lives and improving healthcare through the use of data,” Warner Thomas, president and CEO of Ochsner Health, said in the release.

Truveta was formed in 2020 with the goal of aggregating data across numerous healthcare systems in order to provide medical insights. The release adds that the company has data on about 35 million individuals, which comes out to 16% of healthcare in the U.S.

Truveta has also secured nearly $200 million in funding, following a Series A round from July for $95 million from various healthcare system members and a Microsoft investment for an unknown amount.

The release says Truveta has been de-identifying and aggregating healthcare data, focusing on COVID-19. The data will reportedly give information on vaccinated patients with COVID breakthrough cases, and the system will reportedly only show data from those that have been de-identified and can be analyzed now.

In an early analysis released by the company, which included 1.7 million fully vaccinated patients, it found that patients with some chronic conditions including diabetes and chronic lung diseases or kidney diseases were more likely to be hospitalized with breakthrough COVID cases.

Truveta’s formation was reported previously in PYMNTS, writing that the company was looking at innovating care and making new therapies through its data classifications.

See also: Ex-Microsoft Exec Forms Truveta To Share Anonymized Patient Data

Earlier this year, Truveta CEO Terry Myerson said the pandemic led to the company’s creation because “we do not have the data we needed to know how to take care of our patients, to know which therapeutics worked well.”